Savara Inc Dossier
Qualitative Analysis
Business overview
Savara Inc. (Nasdaq: SVRA) is a clinical-stage biopharmaceutical company focused on the development and commercialization of therapies for rare respiratory diseases. The company's lead product candidate is MOLBREEVI (molgramostim inhalation solution), an inhaled recombinant human granulocyte-macrophage colony-stimulating factor (GM-CSF). MOLBREEVI is in Phase 3 development for the treatment of autoimmune pulmonary alveolar proteinosis (aPAP), a rare and debilitating lung disease characterized by the abnormal build-up of surfactant in the alveoli. The drug is delivered via a proprietary investigational eFlow Nebulizer System developed in partnership with PARI Pharma GmbH. MOLBREEVI has received Fast Track, Breakthrough Therapy, and Orphan Drug designations from the FDA, as well as Orphan Drug designation from the EMA and Innovation Passport status from the UK's MHRA.
Research as of 20 Jun 2026
Strategic Initiatives
Growth programs, investments, and their expected impact
Building out the commercial infrastructure, expanding patient advocacy, medical affairs, and onboarding a dedicated market development team to support the potential global launch of MOLBREEVI.
Expected impact: Successful commercialization and market penetration of MOLBREEVI in the U.S. and international markets, targeting an estimated $2 billion addressable market in the U.S. alone.
Securing non-dilutive funding frameworks to bridge the transition from clinical-stage to commercial-stage without immediate shareholder dilution upon drug approval.
Expected impact: Provides up to $150 million in non-dilutive capital ($75 million from RTW royalty agreement and up to $75 million from amended Hercules Capital debt facility) to fully fund global launch activities.
Mergers, Acquisitions & Partnerships
Recent deals and strategic collaborations
Strategic Partnerships
Provides non-dilutive launch funding of $75 million, which becomes available upon FDA approval of MOLBREEVI, strengthening the balance sheet for U.S. commercialization.
Terms: RTW will receive a tiered single-digit percentage of annual net sales of MOLBREEVI in the U.S. for the treatment of autoimmune PAP, subject to a cap.
Strengthens liquidity and financial flexibility, providing up to $75 million in additional debt funding upon FDA approval of MOLBREEVI.
Terms: Up to $75 million in additional debt capacity becomes available upon FDA approval of MOLBREEVI; loan maturity date and interest-only period remain unchanged with no warrants issued.
Jointly holds patents and provides exclusive access to the proprietary PARI eFlow Nebulizer System optimized specifically for the inhalation delivery of MOLBREEVI.
Terms: Exclusive access to the investigational, proprietary nebulizer system and joint patent coverage extending through March 2043.